These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35618441)

  • 41. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium.
    Ditters IAM; Huidekoper HH; Kruijshaar ME; Rizopoulos D; Hahn A; Mongini TE; Labarthe F; Tardieu M; Chabrol B; Brassier A; Parini R; Parenti G; van der Beek NAME; van der Ploeg AT; van den Hout JMP;
    Lancet Child Adolesc Health; 2022 Jan; 6(1):28-37. PubMed ID: 34822769
    [TBL] [Abstract][Full Text] [Related]  

  • 42. STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa.
    Gutschmidt K; Musumeci O; Díaz-Manera J; Chien YH; Knop KC; Wenninger S; Montagnese F; Pugliese A; Tavilla G; Alonso-Pérez J; Hwu PW; Toscano A; Schoser B
    J Neurol; 2021 Jul; 268(7):2482-2492. PubMed ID: 33543425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Greater Efficacy of Avalglucosidase vs Alglucosidase Alfa in Adult Pompe Disease? The Jury Is Still Out.
    de Visser M; Argov Z
    Neurology; 2022 Aug; 99(5):183-184. PubMed ID: 35618439
    [No Abstract]   [Full Text] [Related]  

  • 44. Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).
    Byrne BJ; Schoser B; Kishnani PS; Bratkovic D; Clemens PR; Goker-Alpan O; Ming X; Roberts M; Vorgerd M; Sivakumar K; van der Ploeg AT; Goldman M; Wright J; Holdbrook F; Jain V; Benjamin ER; Johnson F; Das SS; Wasfi Y; Mozaffar T
    J Neurol; 2024 Apr; 271(4):1787-1801. PubMed ID: 38057636
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.
    Masat E; Laforêt P; De Antonio M; Corre G; Perniconi B; Taouagh N; Mariampillai K; Amelin D; Mauhin W; Hogrel JY; Caillaud C; Ronzitti G; Puzzo F; Kuranda K; Colella P; Mallone R; Benveniste O; Mingozzi F;
    Sci Rep; 2016 Nov; 6():36182. PubMed ID: 27812025
    [TBL] [Abstract][Full Text] [Related]  

  • 46. White matter lesions in treated late onset Pompe disease are not different to matched controls.
    Schneider I; Hensel O; Zierz S
    Mol Genet Metab; 2019 Jun; 127(2):128-131. PubMed ID: 31153821
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years.
    Stepien KM; Hendriksz CJ; Roberts M; Sharma R
    Mol Genet Metab; 2016 Apr; 117(4):413-8. PubMed ID: 26873529
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Higher dosing of alglucosidase alfa improves outcomes in children with Pompe disease: a clinical study and review of the literature.
    Khan AA; Case LE; Herbert M; DeArmey S; Jones H; Crisp K; Zimmerman K; ElMallah MK; Young SP; Kishnani PS
    Genet Med; 2020 May; 22(5):898-907. PubMed ID: 31904026
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term Immunogenicity of Elosulfase Alfa in the Treatment of Morquio A Syndrome: Results From MOR-005, a Phase III Extension Study.
    Long B; Tompkins T; Decker C; Jesaitis L; Khan S; Slasor P; Harmatz P; O'Neill CA; Schweighardt B
    Clin Ther; 2017 Jan; 39(1):118-129.e3. PubMed ID: 27955919
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
    Prescrire Int; 2007 Dec; 16(92):240-1. PubMed ID: 18092404
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enzyme replacement therapy with alglucosidase alfa in a late-onset Pompe disease patient during pregnancy.
    Oliveira Santos M; Evangelista T; Conceição I
    Neuromuscul Disord; 2018 Nov; 28(11):965-968. PubMed ID: 30314719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The emerging phenotype of late-onset Pompe disease: A systematic literature review.
    Chan J; Desai AK; Kazi ZB; Corey K; Austin S; Hobson-Webb LD; Case LE; Jones HN; Kishnani PS
    Mol Genet Metab; 2017 Mar; 120(3):163-172. PubMed ID: 28185884
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort.
    Desai AK; Baloh CH; Sleasman JW; Rosenberg AS; Kishnani PS
    Front Immunol; 2020; 11():1727. PubMed ID: 32849613
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics of Alglucosidase Alfa Manufactured at the 4000-L Scale in Participants with Pompe Disease: A Phase 3/4 Open-Label Study.
    Nicolas X; Hurbin F; Periquet M; Richards S; Sensinger C; Welch K; An Haack K
    Clin Pharmacol Drug Dev; 2023 Dec; 12(12):1185-1193. PubMed ID: 37705424
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry.
    Berger KI; Chien YH; Dubrovsky A; Kishnani PS; Llerena JC; Neilan E; Roberts M; Sheng B; Batista JL; Periquet M; Wilson KM; van der Ploeg AT
    J Neurol; 2024 Jun; ():. PubMed ID: 38896264
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Motor Responses in Pediatric Pompe Disease in the ADVANCE Participant Cohort.
    Duong T; Kishnani PS; An Haack K; Foster MC; Gibson JB; Wilson C; Hahn SH; Hillman R; Kronn D; Leslie ND; Peña LDM; Sparks SE; Stockton DW; Tanpaiboon P; Day JW;
    J Neuromuscul Dis; 2022; 9(6):713-730. PubMed ID: 36214004
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Late-onset Pompe disease (LOPD) in Belgium: clinical characteristics and outcome measures.
    Vanherpe P; Fieuws S; D'Hondt A; Bleyenheuft C; Demaerel P; De Bleecker J; Van den Bergh P; Baets J; Remiche G; Verhoeven K; Delstanche S; Toussaint M; Buyse B; Van Damme P; Depuydt CE; Claeys KG
    Orphanet J Rare Dis; 2020 Apr; 15(1):83. PubMed ID: 32248831
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
    Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
    Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The impact of antibodies in late-onset Pompe disease: a case series and literature review.
    Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS
    Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reveglucosidase alfa (BMN 701), an IGF2-Tagged rhAcid α-Glucosidase, Improves Respiratory Functional Parameters in a Murine Model of Pompe Disease.
    Peng J; Dalton J; Butt M; Tracy K; Kennedy D; Haroldsen P; Cahayag R; Zoog S; O'Neill CA; Tsuruda LS
    J Pharmacol Exp Ther; 2017 Feb; 360(2):313-323. PubMed ID: 27856936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.